Literature DB >> 16126020

Effects of statins on 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition beyond low-density lipoprotein cholesterol.

James K Liao1.   

Abstract

Statins are potent inhibitors of cholesterol biosynthesis and exert beneficial effects in the primary and secondary prevention of coronary artery disease. However, the overall benefits observed with statins appear to occur much earlier and to be greater than what might be expected from changes in lipid levels alone, suggesting effects beyond cholesterol lowering. Indeed, recent studies indicate that some of the cholesterol-independent or "pleiotropic" effects of statins involve improving endothelial function, enhancing the stability of atherosclerotic plaques, decreasing oxidative stress and inflammation, and inhibiting the thrombogenic response. Many of these pleiotropic effects are mediated by inhibition of isoprenoids, which serve as lipid attachments for intracellular signaling molecules. In particular, inhibition of the small guanosine triphosphate-binding proteins Rho, Ras, and Rac, whose proper membrane localization and function are dependent on isoprenylation, may play an important role in mediating the pleiotropic effects of statins.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16126020      PMCID: PMC2684977          DOI: 10.1016/j.amjcard.2005.06.009

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  106 in total

Review 1.  Pleiotropic effects of statins.

Authors:  James K Liao; Ulrich Laufs
Journal:  Annu Rev Pharmacol Toxicol       Date:  2005       Impact factor: 13.820

2.  Platelet deposition on eroded vessel walls at a stenotic shear rate is inhibited by lipid-lowering treatment with atorvastatin.

Authors:  J Alfon; T Royo; X Garcia-Moll; L Badimon
Journal:  Arterioscler Thromb Vasc Biol       Date:  1999-07       Impact factor: 8.311

3.  Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators.

Authors:  P M Ridker; N Rifai; M A Pfeffer; F M Sacks; L A Moye; S Goldman; G C Flaker; E Braunwald
Journal:  Circulation       Date:  1998-09-01       Impact factor: 29.690

4.  Hypercholesterolemia decreases nitric oxide production by promoting the interaction of caveolin and endothelial nitric oxide synthase.

Authors:  O Feron; C Dessy; S Moniotte; J P Desager; J L Balligand
Journal:  J Clin Invest       Date:  1999-03       Impact factor: 14.808

5.  Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators.

Authors:  P M Ridker; N Rifai; M A Pfeffer; F Sacks; E Braunwald
Journal:  Circulation       Date:  1999-07-20       Impact factor: 29.690

6.  Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation.

Authors:  S Dimmeler; I Fleming; B Fisslthaler; C Hermann; R Busse; A M Zeiher
Journal:  Nature       Date:  1999-06-10       Impact factor: 49.962

7.  Regulation of endothelium-derived nitric oxide production by the protein kinase Akt.

Authors:  D Fulton; J P Gratton; T J McCabe; J Fontana; Y Fujio; K Walsh; T F Franke; A Papapetropoulos; W C Sessa
Journal:  Nature       Date:  1999-06-10       Impact factor: 49.962

8.  Combination of fosinopril and pravastatin decreases platelet response to thrombin receptor agonist in monkeys.

Authors:  L P Hale; K T Craver; A M Berrier; M V Sheffield; L D Case; J Owen
Journal:  Arterioscler Thromb Vasc Biol       Date:  1998-10       Impact factor: 8.311

9.  3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors increase fibrinolytic activity in rat aortic endothelial cells. Role of geranylgeranylation and Rho proteins.

Authors:  M Essig; G Nguyen; D Prié; B Escoubet; J D Sraer; G Friedlander
Journal:  Circ Res       Date:  1998-10-05       Impact factor: 17.367

Review 10.  HMG-CoA reductase inhibitor therapy and stroke risk reduction: an analysis of clinical trials data.

Authors:  J R Crouse; R P Byington; C D Furberg
Journal:  Atherosclerosis       Date:  1998-05       Impact factor: 5.162

View more
  62 in total

1.  Mitohormesis: another pleiotropic effect of statins?

Authors:  James K Liao
Journal:  Eur Heart J       Date:  2011-10-06       Impact factor: 29.983

Review 2.  Understanding the pathogenesis of abdominal aortic aneurysms.

Authors:  Helena Kuivaniemi; Evan J Ryer; James R Elmore; Gerard Tromp
Journal:  Expert Rev Cardiovasc Ther       Date:  2015

3.  Lipid-Lowering Agents and High HDL (High-Density Lipoprotein) Are Inversely Associated With Intracranial Aneurysm Rupture.

Authors:  Anil Can; Victor M Castro; Dmitriy Dligach; Sean Finan; Sheng Yu; Vivian Gainer; Nancy A Shadick; Guergana Savova; Shawn Murphy; Tianxi Cai; Scott T Weiss; Rose Du
Journal:  Stroke       Date:  2018-04-05       Impact factor: 7.914

4.  N-3 fatty acid supplementation to routine statin treatment inhibits platelet function, decreases patients' daytime blood pressure, and improves inflammatory status.

Authors:  Keren Doenyas-Barak; Sylvia Berman; Ramzia Abu-Hamad; Ahuva Golik; Naomi Rahimi-Levene; Shai Efrati
Journal:  Eur J Clin Pharmacol       Date:  2012-02-25       Impact factor: 2.953

5.  Early postoperative statin therapy is associated with a lower incidence of acute kidney injury after cardiac surgery.

Authors:  Frederic T Billings; Mias Pretorius; Edward D Siew; Chang Yu; Nancy J Brown
Journal:  J Cardiothorac Vasc Anesth       Date:  2010-12       Impact factor: 2.628

Review 6.  Stabilization of high-risk plaques.

Authors:  Kohei Takata; Satoshi Imaizumi; Bo Zhang; Shin-Ichiro Miura; Keijiro Saku
Journal:  Cardiovasc Diagn Ther       Date:  2016-08

7.  Farnesyl pyrophosphate inhibits epithelialization and wound healing through the glucocorticoid receptor.

Authors:  Sasa Vukelic; Olivera Stojadinovic; Irena Pastar; Constantinos Vouthounis; Agata Krzyzanowska; Sharmistha Das; Herbert H Samuels; Marjana Tomic-Canic
Journal:  J Biol Chem       Date:  2009-11-10       Impact factor: 5.157

8.  Bone marrow endothelial progenitors in atherosclerotic plaque resolution.

Authors:  Longbiao Yao; Janet Heuser-Baker; Oana Herlea-Pana; Jana Barlic-Dicen
Journal:  Organogenesis       Date:  2013-01-01       Impact factor: 2.500

9.  Atorvastatin in stroke: a review of SPARCL and subgroup analysis.

Authors:  Branko N Huisa; Andrew B Stemer; Justin A Zivin
Journal:  Vasc Health Risk Manag       Date:  2010-04-15

10.  Simvastatin protects against amyloid beta and HIV-1 Tat-induced promoter activities of inflammatory genes in brain endothelial cells.

Authors:  Ibolya E András; Geunbae Rha; Wen Huang; Sungyong Eum; Pierre-Olivier Couraud; Ignacio A Romero; Bernhard Hennig; Michal Toborek
Journal:  Mol Pharmacol       Date:  2008-02-14       Impact factor: 4.436

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.